Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer -

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Information type: Other primary research
Source: Journal of Clinical Oncology
Specialities: Cancers
Summary
In this phase 2 trial (n=69) in patients who had received a median of 5 prior therapies the confirmed objective response rate (partial or complete response) was 30% and the clinical benefit rate (complete response + partial response + stable disease ≥ 6 months) was 46%.
UKMi comment
Sacituzumab govitecan is an antibody-drug conjugate comprising hRS7, a humanised antibody that binds to the trophoblast cell-surface antigen (TROP-2), and SN-38 which is the active metabolite of irinotecan.
Related links: